Table 2 Characteristics of metastatic lesions and preoperative medication used to prevent adrenergic responsea
Characteristic | First Ablation (n = 21) | All Ablations (N = 38) |
|---|---|---|
Primary tumor location | ||
Abdomen | 8 (38) | 15 (39) |
Retroperitoneal | 3 (14) | 6 (16) |
Liver | 1 (5) | 1 (3) |
Adrenal | 6 (29) | 11 (29) |
Head/neck | 2 (10) | 4 (11) |
Spine | 1 (5) | 1 (3) |
Procedure | ||
Cryoablation | 5 (24) | 10 (26) |
RFA | 15 (71) | 24 (63) |
Cryoablation + RFA | 0 (0) | 4 (11) |
Ablation single location | ||
Vertebral body | 3 (14) | 8 (21) |
Bone | 6 (29) | 7 (18) |
Bladder/urethra | 0 (0) | 1 (3) |
Liver | 9 (43) | 12 (32) |
Ablation multiple locations | ||
Vertebral body + other bones | 1 (5) | 8 (21) |
Liver + other bones | 1 (5) | 1 (3) |
Adrenal gland + liver | 1 (5) | 1 (3) |
Functional tumors | 15 (71) | 24 (63) |
Preoperative adrenergic blockers | ||
Any treatment | 19 (90) | 31 (82) |
α-blocker, β-blocker, CCB combinations | ||
α1,2 + β + CCB | 0 (0) | 2 (5) |
α1 only | 2 (10) | 2 (5) |
α1,2 + β | 9 (43) | 16 (42) |
α1 + β | 0 (0) | 3 (8) |
α1 + CCB | 2 (10) | 2 (5) |
α1,2 only | 5 (24) | 5 (13) |
None (α/β/CCB/metyrosine) | 3 (14) | 8 (21) |
Metyrosine | 7 (33) | 11 (29) |